Prostate-specific antigen velocity: New methods, same results, still no evidence of clinical utility

European Urology

Volumn 64, Issue 3, 2013, Pages 394-396

  Vickers, Andrew J ^a   Pencina, Michael J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DISEASE MARKER; GLEASON SCORE; LUNG CANCER; MEDICAL PARAMETERS; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY; REVIEW; RISK ASSESSMENT; TUMOR BIOPSY;

HUMANS; KALLIKREINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84881147567     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.003     Document Type: Editorial

References (13)

1. T. Wolters, M.J. Roobol, C.H. Bangma, and F.H. Schröder Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam) Eur Urol 55 2009 385 393
2. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534
3. K. Fall, H. Garmo, and O. Andrén Scandinavian Prostate Cancer Group Study No. 4. Prostate-specific antigen levels as a predictor of lethal prostate cancer J Natl Cancer Inst 99 2007 526 532
4. P.F. Pinsky, G. Andriole, and E.D. Crawford Prostate-specific antigen velocity and prostate cancer Gleason grade and stage Cancer 109 2007 1689 1695
5. G.L. Andriole, D. Bostwick, O.W. Brawley REDUCE Study Group The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study J Urol 185 2011 126 131
6. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810 2816
7. D. Ulmert, A.M. Serio, and M.F. O'Brien Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 2008 835 841
8. D.D. Ørsted, S.E. Bojesen, P.R. Kamstrup, and B.G. Nordestgaard Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality Eur Urol 64 2013 384 393
9. M.J. Pencina, R.B. D'Agostino, K.M. Pencina, A.C. Janssens, and P. Greenland Interpreting incremental value of markers added to risk prediction models Am J Epidemiol 176 2012 473 481
10. Prostate cancer detection (Version 1.2007). National Comprehensive Cancer Network 2007. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
11. A.J. Vickers, C. Till, C.M. Tangen, H. Lilja, and I.M. Thompson An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection J Natl Cancer Inst 103 2011 462 469
12. A.J. Vickers, T. Wolters, and C.J. Savage Prostate-specific antigen velocity for early detection of prostate cancer: Result from a large, representative, population-based cohort Eur Urol 56 2009 753 760
13. S.E. Eggener, O. Yossepowitch, K.A. Roehl, S. Loeb, X. Yu, and W.J. Catalona Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program Urology 71 2008 1016 1019